Phase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation stage, with announcement of recommended Phase 2 dose and Phase 1...
TROY, Mich., Feb. 24, 2022 (GLOBE NEWSWIRE) — Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence today released its financial results for...
Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022 Phase 1b study in Cognitive...
GUILFORD, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) — InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug discovery...
LOUISVILLE, Ky., Feb. 24, 2022 (GLOBE NEWSWIRE) — Healthcare is hard. And, when it comes to HCC Risk Adjustment, obstacles like inefficiencies & inaccuracies often crop...
New York, NY, Feb. 24, 2022 (GLOBE NEWSWIRE) — The Association for Computing Machinery’s global Technology Policy Council (ACM TPC) today released, “ACM TechBrief: Facial Recognition,”...
THE WOODLANDS, Texas, Feb. 24, 2022 (GLOBE NEWSWIRE) — via InvestorWire — SPYR, Inc. dba SPYR Technologies (OTCQB: SPYR) (https://spyr.com), a technology company whose subsidiary, Applied...
Dublin, Feb. 24, 2022 (GLOBE NEWSWIRE) — The “Neobanking Market Size, Share & Trends Analysis Report by Account Type (Business, Savings), by Application (Enterprises, Personal), by...
OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β OT-101 has completed over six clinical trials against solid tumors with good efficacy OT-101 is currently undergoing a phase...
SALT LAKE CITY, Feb. 24, 2022 (GLOBE NEWSWIRE) — OMNIQ Corp. (NASDAQ: OMQS) (“OMNIQ” or “the Company”), a provider of Supply Chain and Artificial Intelligence (AI)-based solutions...